Efficacy and safety profile of 2-year netakimab treatment in patients with moderate-to-severe plaque psoriasis in terms of the randomized double-blind placebo-controlled BCD-085-7/PLANETA clinical trial

• Ngā kaituhi matua: Andrey I. Bakulev (Author), Alexey V. Samtsov (Author), Evgeny V. Sokolovskiy (Author), Muza M. Kokhan (Author), Marianna M. Khobeish (Author), Vladislav R. Khairutdinov (Author), Arfenya E. Karamova (Author), Olga U. Olisova (Author), Dmitry V. Ignatiev (Author), Aleksandra N. Nikiforova (Author), Antonina V. Artemeva (Author), Arina V. Zinkina-Orikhan (Author)
• Hōputu: Pukapuka
• I whakaputaina: State Scientific Center of Dermatovenereology and Cosmetology, 2022-05-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Background. Netakimab, a recombinant humanized monoclonal antibody, specifically binding to IL-17 blocks its activity resulting in plaque psoriasis signs decrease. The results of the first year of BCD-085-7/PLANETA study showed high efficacy and a favorable safety profile in the treatment of patient...